JP2020524679A - カンナビジオール酸エステル組成物およびその使用 - Google Patents

カンナビジオール酸エステル組成物およびその使用 Download PDF

Info

Publication number
JP2020524679A
JP2020524679A JP2019570108A JP2019570108A JP2020524679A JP 2020524679 A JP2020524679 A JP 2020524679A JP 2019570108 A JP2019570108 A JP 2019570108A JP 2019570108 A JP2019570108 A JP 2019570108A JP 2020524679 A JP2020524679 A JP 2020524679A
Authority
JP
Japan
Prior art keywords
chain
branched
disease
compound according
straight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019570108A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524679A5 (https=
Inventor
メコーラム，ラファエル
パーカー，リンダ
パートウィー，ロジャー
ウェラー，アロン
タム，ヨセフ
ハジ，クリスティーン
スマム，リーム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bar Ilan University
Original Assignee
Bar Ilan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bar Ilan University filed Critical Bar Ilan University
Publication of JP2020524679A publication Critical patent/JP2020524679A/ja
Publication of JP2020524679A5 publication Critical patent/JP2020524679A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/94—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • C07C69/16—Acetic acid esters of dihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/28—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2019570108A 2017-06-20 2018-06-20 カンナビジオール酸エステル組成物およびその使用 Pending JP2020524679A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762522243P 2017-06-20 2017-06-20
US62/522,243 2017-06-20
PCT/IL2018/050678 WO2018235079A1 (en) 2017-06-20 2018-06-20 CANNABIDIOLIC ACID ESTER COMPOSITIONS AND USES THEREOF

Publications (2)

Publication Number Publication Date
JP2020524679A true JP2020524679A (ja) 2020-08-20
JP2020524679A5 JP2020524679A5 (https=) 2021-07-26

Family

ID=62875079

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019570108A Pending JP2020524679A (ja) 2017-06-20 2018-06-20 カンナビジオール酸エステル組成物およびその使用

Country Status (12)

Country Link
US (1) US11440870B2 (https=)
EP (1) EP3509638B1 (https=)
JP (1) JP2020524679A (https=)
CN (2) CN121534035A (https=)
AU (1) AU2018287018B2 (https=)
BR (1) BR112019026916A2 (https=)
CA (1) CA3067512A1 (https=)
DK (1) DK3509638T3 (https=)
ES (1) ES2909350T3 (https=)
MX (1) MX389847B (https=)
PT (1) PT3509638T (https=)
WO (1) WO2018235079A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
EP3509638B1 (en) 2017-06-20 2022-01-12 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Cannabidiolic acid esters compositions and uses thereof
CA3089994A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
WO2020077153A1 (en) 2018-10-10 2020-04-16 Canopy Holdings, LLC Synthesis of cannabigerol
WO2020136648A1 (en) * 2018-12-25 2020-07-02 Epm Group Inc. Cannabidiolic acid esters for cosmetic or edible compositions
US12403114B2 (en) 2019-03-12 2025-09-02 Epm (Ip), Inc. Cannabinoid acid ester compositions and uses thereof
WO2021034403A1 (en) 2019-08-22 2021-02-25 Epm Group, Inc. Cannabinoid acid ester compositions and uses thereof
WO2021137224A1 (en) * 2020-01-01 2021-07-08 Epm Group, Inc. Cannabidiolic acid esters for treating muscular dystrophy
IL275108A (en) * 2020-06-03 2022-01-01 Epm Ip Inc Abnormal acid cannabidiol (abn-cbd) derivatives and their uses
WO2022103639A1 (en) * 2020-11-16 2022-05-19 Orcosa Inc. Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
IL303739A (en) * 2020-12-24 2023-08-01 Buzzelet Development And Technologies Ltd Compositions including cannabinoid esters
US20230066947A1 (en) * 2021-08-04 2023-03-02 Max Hammond Method for the augmentation of substance abuse therapies using cannabinoid formulations

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009510078A (ja) * 2005-09-29 2009-03-12 エーエムアール テクノロジー インコーポレイテッド Δ−９−テトラヒドロカンナビノールの生成法
WO2010045813A1 (zh) * 2008-10-22 2010-04-29 华为终端有限公司 系统端和终端的交互媒体文档更新方法及装置
US20100298579A1 (en) * 2009-04-29 2010-11-25 Thc Pharm Gmbh Process for preparing synthetic cannabinoids
WO2015158381A1 (en) * 2014-04-16 2015-10-22 Vivacell Biotechnology España S.L. Novel cannabidiol quinone derivatives
JP2016531919A (ja) * 2013-09-03 2016-10-13 シムライズ アーゲー カンナビノイド化合物の組成物、その製造及び使用
CN106810426A (zh) * 2016-12-29 2017-06-09 暨明医药科技（苏州）有限公司 一种大麻二酚的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2318468A1 (fr) 1975-07-17 1977-02-11 Jaeger Dispositif electronique d'enregistrement et de lecture de donnees concernant differents parametres au cours d'un cycle predetermine, fonction de l'un desdits parametres
US5342971A (en) 1992-12-29 1994-08-30 The Australian National University Process for the preparation of dibenzo[b,d]pyrans
ATE277921T1 (de) 1998-05-04 2004-10-15 Univ Connecticut Selektiv auf den cb2-rezeptor wirkende cannabinoide
IL136839A (en) 2000-06-16 2006-12-10 Yissum Res Dev Co Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same
JP2008502690A (ja) 2004-06-15 2008-01-31 アンドリュー シァン チェン， リン脂質組成物ならびにその調製方法および使用方法
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2494461A (en) 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
GB2515312A (en) 2013-06-19 2014-12-24 Gw Pharma Ltd The use of phytocannabinoids in the treatment of ovarian carcinoma
GB2527590A (en) 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
GB2531283A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiols in the treatment of degenerative skeletal muscle diseases
EP3061450A1 (de) 2015-02-26 2016-08-31 Symrise AG Mischungen cannabinoider Verbindungen, deren Herstellung und Verwendung
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
EP3509638B1 (en) 2017-06-20 2022-01-12 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Cannabidiolic acid esters compositions and uses thereof
WO2019234728A1 (en) 2018-06-04 2019-12-12 Al&Am Pharmachem Ltd. Cannabinolic acid derivatives and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009510078A (ja) * 2005-09-29 2009-03-12 エーエムアール テクノロジー インコーポレイテッド Δ−９−テトラヒドロカンナビノールの生成法
WO2010045813A1 (zh) * 2008-10-22 2010-04-29 华为终端有限公司 系统端和终端的交互媒体文档更新方法及装置
US20100298579A1 (en) * 2009-04-29 2010-11-25 Thc Pharm Gmbh Process for preparing synthetic cannabinoids
JP2016531919A (ja) * 2013-09-03 2016-10-13 シムライズ アーゲー カンナビノイド化合物の組成物、その製造及び使用
WO2015158381A1 (en) * 2014-04-16 2015-10-22 Vivacell Biotechnology España S.L. Novel cannabidiol quinone derivatives
CN106810426A (zh) * 2016-12-29 2017-06-09 暨明医药科技（苏州）有限公司 一种大麻二酚的合成方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL & PHARMACEUTICAL BULLETIN, vol. Vol.25(9), JPN6022021291, 1977, pages 2306 - 2311, ISSN: 0004925760 *
HELVETICA CHIMICA ACTA, vol. Vol.52(4), JPN6022021295, 1969, pages 1102 - 1134, ISSN: 0004925759 *

Also Published As

Publication number Publication date
BR112019026916A2 (pt) 2020-06-30
EP3509638A1 (en) 2019-07-17
AU2018287018A1 (en) 2020-01-30
AU2018287018B2 (en) 2022-04-28
WO2018235079A1 (en) 2018-12-27
ES2909350T3 (es) 2022-05-06
EP3509638B1 (en) 2022-01-12
CA3067512A1 (en) 2018-12-27
PT3509638T (pt) 2022-03-02
DK3509638T3 (da) 2022-04-11
CN121534035A (zh) 2026-02-17
US20200115317A1 (en) 2020-04-16
MX2019015311A (es) 2022-02-02
CN111032088A (zh) 2020-04-17
MX389847B (es) 2025-03-20
US11440870B2 (en) 2022-09-13

Similar Documents

Publication Publication Date Title
JP2020524679A (ja) カンナビジオール酸エステル組成物およびその使用
US20250074873A1 (en) Compounds
CN102850317B (zh) 一种取代桂皮酰胺衍生物、制备方法及其应用
NZ605887A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
CO6361928A2 (es) Modulares de aril metil benzoquinazolinona alostericos positivos del receptor m1
WO2016105449A1 (en) Compounds for use as pain therapeutics
CN113795248A (zh) 带电荷的离子通道阻滞剂及其使用方法
CN115279731B (zh) 带电的离子通道阻滞剂及其使用方法
CA2781436A1 (en) Arachidonic acid analogs and methods for analgesic treatment using same
CN113924094A (zh) 酯取代的离子通道阻滞剂及其使用方法
TW201805283A (zh) sGC刺激劑之固體形式
EP3016944A1 (en) Compounds for treatment of cystic fibrosis
WO2020093098A1 (en) Novel compounds for the treatment of respiratory diseases
AU2001247649A1 (en) N-substituted dithiocarbamates for the treatment of biological disorders
ES2856204T3 (es) Compuestos de ciclohexenilo, composiciones que los comprenden y usos de los mismos
WO2009024103A3 (en) Natural brassinosteroids for use for treating hyperproliferation, treating proliferative diseases and reducing adverse effects of steroid dysfunction in mammals, pharmaceutical composition and its use
US20110086910A1 (en) Method of treating or preventing pain
CN107021961A (zh) 一类具有辐射防护作用的新化合物、其制备方法及其药物应用
RU2008110933A (ru) Применение амброксола для лечения риновирусных инфекций
JP2020527156A5 (https=)
CN108218814A (zh) 靶向sirt3激动剂及其在aml治疗药物中的应用
HK40028173A (en) Cannabidiolic acid esters compositions and uses thereof
CN113015524A (zh) 氨基甲酸酯化合物和包含其的制剂在预防、缓解或治疗急性应激障碍或创伤后应激障碍中的用途
CN103919776B (zh) 一种治疗关节炎的药物组合物
WO2007093587A1 (en) Use of r-(-)-2,4-diamino-5-(2, 3-dichlorophenyl)-6-fluoromethyl pyrimidine for the treatment of psychotic disorders

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210607

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210607

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220825

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221122